Key facts
- It has raised $12.4M; the latest was Seed Round ($8.7M) in Apr 2026.
- Notable investors include Quiet Capital, Panache Ventures, Golden Ventures, Peter Thiel, OpenAI — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Biossil
- ·The full record, as it builds
Funding rounds
No funding rounds for Biossil are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Biossil
Developer of an artificial intelligence drug discovery platform designed to offer targeted therapies for biologically defined patient sub-populations. The company's platform offers Excavate, which combines a data-point multi-omics pipeline with population-scale electronic medical record data to translate disease sub-phenotypes into molecular endotypes defined by interactome-scale disease modules, enabling medical researchers to cut drug repurposing time and bring shelved therapies to trial faster.
- Sector
- Healthcare
- HQ
- Toronto, Canada
- Founded
- 2023
- Employees
- 4
- Website
- biossil.co/
- Ownership
- Privately Held (backing)
Biossil doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Biossil shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Biossil in its N-PORT filings yet. We sweep new filings monthly.